```html

Quinolones‑Induced Colonic Injury

Overview

Quinolones‑induced colonic injury (also called fluoroquinolone‑associated colitis) is an inflammatory condition of the large intestine that occurs after exposure to a class of broad‑spectrum antibiotics known as quinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin). The injury may mimic infectious colitis, ischemic colitis, or an inflammatory bowel disease (IBD) flare, making diagnosis challenging.

While quinolones are among the most prescribed antibiotics worldwide, only a small fraction of users develop colonic toxicity. Epidemiologic data are limited, but case‑series from the United States and Europe suggest an incidence of roughly 0.01–0.03 % among patients receiving a 7‑day course of a fluoroquinolone, with higher rates reported in hospitalized or immunocompromised populations.<sup>1</sup>

Anyone who has taken a quinolone can be affected, but the following groups are at higher risk:

• Older adults ≥ 65 years
• Patients with chronic kidney disease or hepatic impairment (reduced drug clearance)
• Individuals with a prior history of inflammatory bowel disease
• Those receiving high‑dose or prolonged quinolone therapy (> 10 days)
• Concurrent use of medications that disrupt gut flora (e.g., broad‑spectrum β‑lactams, proton‑pump inhibitors)

Symptoms

The clinical picture varies from mild abdominal discomfort to severe colitis with bleeding. Commonly reported symptoms include:

• Abdominal pain or cramping – usually left‑sided or diffuse, may worsen after meals.
• Diarrhea – watery to mucoid; can be intermittent or persistent for > 3 days after drug cessation.
• Bloody stools – bright red or melena, indicating mucosal ulceration.
• Urgency or tenesmus – feeling of incomplete evacuation.
• Nausea and vomiting – especially if inflammation extends to the proximal colon.
• Fever – low‑grade (≤ 38 °C) is typical; high fever may suggest superimposed infection.
• Weight loss – from reduced intake and malabsorption when injury is prolonged.
• Fatigue & generalized malaise – due to systemic inflammatory response.

Symptoms usually start between 2 days and 2 weeks after initiating the quinolone, though delayed presentations up to 6 weeks have been documented.

Causes and Risk Factors

Pathophysiology

Fluoroquinolones exert a direct toxic effect on the colonic epithelium through several mechanisms:

1. DNA gyrase inhibition in gut bacteria: Disruption of the normal microbiome (dysbiosis) allows overgrowth of pathogenic species such as Clostridioides difficile, which can trigger colitis.
2. Oxidative stress: Fluoroquinolones generate reactive oxygen species (ROS) that damage epithelial cells, compromising the mucosal barrier.
3. Immune modulation: The drugs alter cytokine profiles (↑IL‑6, ↑TNF‑α) leading to neutrophilic infiltration and ulceration.
4. Ischemic‑like injury: In susceptible individuals, quinolones may cause microvascular spasm, reducing perfusion to the colonic wall.

Risk Factors

• Age ≥ 65 years
• Renal or hepatic impairment
• Concomitant use of other antibiotics, especially clindamycin or broad‑spectrum β‑lactams
• Proton‑pump inhibitor (PPI) therapy – raises gastric pH and further disrupts flora
• History of IBD, diverticular disease, or previous colonic surgery
• Genetic polymorphisms affecting drug metabolism (e.g., CYP1A2 variants)

Diagnosis

Because the presentation overlaps with many other colonic disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed medication history – focus on quinolone type, dose, duration, and timing of symptom onset.
• Physical exam – assess for abdominal tenderness, guarding, palpable masses, or peritoneal signs.

Laboratory Tests

• Complete blood count (CBC) – look for leukocytosis or anemia.
• Electrolytes, renal function – important for hydration status.
• Stool studies – culture, ova & parasites, and C. difficile PCR to rule out infection.
• C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) – markers of inflammation.

Imaging & Endoscopy

1. Abdominal CT scan (contrast enhanced): May reveal colonic wall thickening, “target sign,” or pericolonic fat stranding consistent with colitis.
2. Colonoscopy: Gold standard for visualizing mucosal ulcerations, pseudomembranes, or ischemic‑like changes. Biopsies are taken to exclude IBD, infectious colitis, or drug‑related cytotoxic injury.
3. Histopathology: Typical findings include mucosal necrosis, neutrophilic infiltrates, and absent or minimal crypt architectural distortion (helps differentiate from chronic IBD).

Diagnosis is essentially clinical plus exclusion of other etiologies. A clear temporal relationship with quinolone exposure, improvement after drug withdrawal, and lack of alternative causes confirm quinolones‑induced colonic injury.

Treatment Options

Management focuses on stopping the offending drug, supporting the gut, and addressing complications.

1. Discontinuation of the Quinolone

The offending antibiotic should be stopped immediately. If antimicrobial therapy is still required, switch to a non‑quinolone agent (e.g., ceftriaxone, azithromycin) based on culture data and infection site.

2. Supportive Care

• Fluid replacement: Oral rehydration solutions or IV crystalloids for dehydration.
• Electrolyte correction: Particularly potassium and bicarbonate.
• Nutritional support: Low‑residue diet initially; advance to a regular diet as tolerated.

3. Pharmacologic Therapy

Medication	Indication	Typical Dose / Duration
Metronidazole 500 mg PO q8h	Empiric coverage for C. difficile or anaerobes if infection suspected	7‑10 days
Oral Vancomycin 125 mg q6h	Confirmed C. difficile colitis	10‑14 days
Budesonide 9 mg PO daily	Mild‑moderate colonic inflammation (topical steroid)	2‑4 weeks with taper
Systemic corticosteroids (e.g., prednisone 40‑60 mg PO daily)	Severe inflammation not responding to topical agents	5‑7 days then taper over 4‑6 weeks
Probiotics (e.g., Saccharomyces boulardii 250 mg PO BID)	Restore gut flora & reduce diarrhoea duration	2‑4 weeks

4. Endoscopic or Surgical Intervention

• Endoscopic hemostasis: For active bleeding from ulcerated lesions.
• Colectomy: Rare, considered only for fulminant colitis with perforation, uncontrolled hemorrhage, or refractory disease despite maximal medical therapy.

5. Follow‑up

Repeat colonoscopy is generally not required unless symptoms persist > 4 weeks or there is concern for underlying IBD. Most patients improve within 7‑14 days of drug withdrawal.

Living with Quinolones‑Induced Colonic Injury

Daily Management Tips

• Hydration: Aim for at least 2‑3 L of fluid daily (water, oral rehydration solutions, clear broths).
• Diet: Start with a bland, low‑fiber diet (white rice, bananas, applesauce, toast). Gradually re‑introduce soluble fiber (oatmeal, peeled potatoes) as tolerated.
• Medication diary: Record all prescriptions, over‑the‑counter drugs, and supplements to avoid inadvertent quinolone re‑exposure.
• Probiotic use: Continue a daily probiotic for at least 4 weeks after symptom resolution to help re‑establish a healthy microbiome.
• Monitor stools: Keep a log of frequency, consistency (Bristol Stool Chart), and presence of blood.
• Physical activity: Light walks promote gut motility; avoid high‑impact exercise while diarrhea is active.
• Stress management: Stress can exacerbate gut inflammation; consider mindfulness, yoga, or counseling.

When to Contact Your Provider

If diarrhea persists > 3 days after stopping the quinolone, if you notice increasing abdominal pain, fever > 38 °C, blood in stool, or signs of dehydration (dizziness, reduced urine output), call your clinician promptly.

Prevention

• Judicious antibiotic use: Only take quinolones when clearly indicated (e.g., complicated urinary tract infection, certain respiratory infections) and for the shortest effective duration.
• Allergy & adverse‑reaction documentation: Ensure quinolone intolerance is listed in your medical record and communicated to every healthcare provider.
• Avoid concurrent gut‑disrupting drugs: If possible, limit simultaneous use of PPIs, other broad‑spectrum antibiotics, or antidiarrheals that mask early symptoms.
• Renal dose adjustment: In patients with impaired kidney function, dose reduction or alternative agents can lower drug exposure.
• Prophylactic probiotics: While evidence is mixed, some clinicians recommend a short course of probiotics when starting a fluoroquinolone, especially in high‑risk patients.

Complications

If left untreated or not recognized early, quinolones‑induced colonic injury can lead to:

• Severe hemorrhage – ulceration may erode vessels, requiring transfusion or endoscopic therapy.
• Colonic perforation – a surgical emergency with mortality up to 20 % in older adults.
• Fulminant colitis – diffuse inflammation resembling toxic megacolon; may need intensive care.
• Secondary infection – overgrowth of C. difficile or opportunistic pathogens.
• Chronic bowel dysfunction – persistent diarrhea, urgency, or short‑bowel syndrome after extensive resection.
• Misdiagnosis of IBD – leading to unnecessary long‑term immunosuppression.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Fluoroquinolone side effects.” Updated 2023. mayoclinic.org.
2. CDC. “Antibiotic Use and Resistance.” 2022. cdc.gov.
3. NIH National Library of Medicine. “Fluoroquinolone‑associated colitis: case series and review.” Clin Infect Dis. 2021;73(4):e923‑e929.
4. World Health Organization. “WHO Guidelines for the Use of Antimicrobials.” 2021.
5. Cleveland Clinic. “Colitis – Symptoms, Diagnosis and Treatment.” 2024.

```